Screening and early diagnosis of pancreatic cancer are at the focal point of attention from researchers, physicians and patients. A new systematic review and recommendation statement by the USPSTF attempt to summarize the current state of affairs.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin. 67, 7–30 (2017).
Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913–2921 (2014).
National Cancer Institute. Cancer stat facts: pancreatic cancer. Cancer.gov https://seer.cancer.gov/statfacts/html/pancreas.html (2018).
Nora, B. et al. Screening for pancreatic cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 322, 445–454 (2019).
US Preventive Services Task Force. Screening for pancreatic cancer: US Preventive Services Task Force reaffirmation recommendation statement. JAMA 322, 438–444 (2019).
Yu, J. et al. Time to progression of pancreatic ductal; adenocarcinoma from low-to-high tumor stages. Gut 64, 1783–1789 (2015).
Canto, M. I. et al. International Cancer of the Pancreas Screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62, 339–347 (2013).
Kneuertz, P. J. et al. Risk of morbidity and mortality following hepato-pancreato-biliary surgery. J. Gastrointest. Surg. 16, 1727–1735 (2012).
Cristiano, S. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 85–389 (2019).
Chu, L. C. et al. Utility of CT radiomics features in differentiation of pancreatic ductal adenocarcinoma from normal pancreatic tissue. Am. J. Roentgenol. 213, 349–357 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has acted as consultant and lecturer for, and received financial support from, Boston Scientific, Cook Medical and Pentax Medical. The author has also acted as consultant for Mylan and has received financial support and lecture work from 3M.
Rights and permissions
About this article
Cite this article
Bruno, M.J. Pancreatic cancer screening — is it prime time yet?. Nat Rev Gastroenterol Hepatol 16, 709–710 (2019). https://doi.org/10.1038/s41575-019-0221-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-019-0221-z
